NRG ONCOLOGY STUDY BN007: RANDOMIZED PHASE II/III TRIAL OF IPILIMIUMAB (IPI) PLUS NIVOLUMAB (NIVO) VS. TEMOZOLOMIDE (TMZ) IN MGMT-UNMETHYLATED (UMGMT) NEWLY DIAGNOSED GLIOBLASTOMA (NGBM)

被引：0

作者：

Lassman, A. B. ^{[1
,2
,3
]}

Polley, M. C. ^{[4
,5
]}

Iwamoto, F. M. ^{[1
,2
,3
]}

Sloan, A. E. ^{[6
]}

Wang, T. J. C. ^{[2
,3
,7
]}

Aldape, K. D. ^{[8
]}

Wefel, J. S. ^{[9
]}

Gondi, V. ^{[10
]}

Gutierrez, A. N. ^{[11
]}

Manasawala, M. ^{[12
]}

Gilbert, M. R. ^{[13
]}

Sulman, E. P. ^{[14
]}

Wolchok, J. D. ^{[2
,15
]}

Greene, R. M. ^{[16
]}

Neil, E. C. ^{[17
]}

Lukas, R. V. ^{[18
]}

Goldlust, S. A. ^{[19
]}

Snuderl, M. ^{[20
]}

Dignam, J. J. ^{[4
,5
]}

Won, M. ^{[4
,21
]}

Movsas, B. ^{[22
]}

Mehta, M. P.

机构：

[1] Columbia Univ, Dept Neurol, Div Neurooncol, Vagelos Coll Phys & Surg, New York, NY USA

[2] New York Presbyterian, New York, NY USA

[3] Herbert Irving Comprehens Canc Ctr, New York, NY USA

[4] NRG Oncol Stat & Data Management Ctr, Philadelphia, PA USA

[5] Univ Chicago, Chicago, IL USA

[6] Piedmont Hlth, Atlanta, GA USA

[7] Columbia Univ, Vagelos Coll Phys & Surg, Dept Radiat Oncol Neurol Surg, New York, NY USA

[8] NCI, Bethesda, MD USA

[9] Univ Texas MD Anderson Canc Ctr, Houston, TX USA

[10] Northwestern Med Canc Ctr Warrenville, Warrenville, IL USA

[11] Miami Canc Inst, Miami, FL USA

[12] WellSpan Hlth York Canc Ctr, York, PA USA

[13] NIH, Ctr Clin, Bethesda, MD USA

[14] New York Univ Grossman Sch Med, Laura & Isaac Perlmutter Canc Ctr, NYU Langone Hlth, New York, NY USA

[15] Weill Cornell Med, Meyer Canc Ctr, New York, NY USA

[16] Kaiser Permanente Los Angeles Med Ctr, Accrual Kaiser Permanente NCI Community Oncol Res, Los Angeles, CA USA

[17] M Hlth Fairview Canc Ctr, Accruals Metro Minnesota Community Oncol Res Cons, Minneapolis, MN USA

[18] Northwestern Univ, Chicago, IL USA

[19] Accruals Hackensack Univ, St Lukes Canc Inst, Med Ctr, Kansas City, MO USA

[20] NYU, New York, NY USA

[21] Amer Coll Radiol Stat & Data Management Ctr, Philadelphia, PA USA

[22] Henry Ford Hosp, Detroit, MI USA

来源：

NEURO-ONCOLOGY | 2023年 / 25卷

关键词：

D O I：

10.1093/neuonc/noad137.005

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

PL02.3.A

引用

页数：1

共 11 条

[1] NRG ONCOLOGY STUDY BN007: RANDOMIZED PHASE II/III TRIAL OF IPILIMIUMAB (IPI) PLUS NIVOLUMAB (NIVO) VS. TEMOZOLOMIDE (TMZ) IN MGMT-UNMETHYLATED (UMGMT) NEWLY DIAGNOSED GLIOBLASTOMA (NGBM)
Lassman, Andrew
Polly, Mei-Yin
Iwamoto, Fabio
Sloan, Andrew
Wang, Tony
Aldape, Kenneth
Wefel, Jeffrey
Gondi, Vinai
Gutierrez, Alonson
Manasawala, Mohammed
Gilbert, Mark
Sulman, Erik
Wolchok, Jedd
Green, Richard
Neil, Elizabeth
Lukas, Rimas
Goldlust, Samuel
Snuderl, Matija
Dignam, James
Won, Minhee
Movsas, Benjamin
Mehta, Minesh
NEURO-ONCOLOGY, 2023, 25
[2] Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: An international randomized phase III trial
Omuro, Antonio
Brandes, Alba A.
Carpentier, Antoine F.
Idbaih, Ahmed
Reardon, David A.
Cloughesy, Timothy
Sumrall, Ashley
Baehring, Joachim
van den Bent, Martin
Bahr, Oliver
Lombardi, Giuseppe
Mulholland, Paul
Tabatabai, Ghazaleh
Lassen, Ulrik
Sepulveda, Juan Manuel
Khasraw, Mustafa
Vauleon, Elodie
Muragaki, Yoshihiro
Di Giacomo, Anna Maria
Butowski, Nicholas
Roth, Patrick
Qian, Xiaozhong
Fu, Alex Z.
Liu, Yanfang
Potter, Von
Chalamandaris, Alexandros-Georgios
Tatsuoka, Kay
Lim, Michael
Weller, Michael
NEURO-ONCOLOGY, 2023, 25 (01) : 123 - 134
[3] A RANDOMIZED PHASE II TRIAL OF VELIPARIB (V), RADIOTHERAPY (RT) AND TEMOZOLOMIDE (TMZ) IN PATIENTS (PTS) WITH UNMETHYLATED MGMT (uMGMT) GLIOBLASTOMA (GBM): THE VERTU STUDY
Khasraw, Mustafa
McDonald, Kerrie Leanne
Rosenthal, Mark
Lwin, Zarnie
Ashley, David
Wheeler, Helen
Barnes, Elizabeth
Foote, Matthew
Koh, Eng-Siew
Sulman, Erik
Back, Michael
Buckland, Michael
Sim, Hao-Wen
Fisher, Lauren
Leonard, Robyn
Hall, Merryn
Yip, Sonia
Simes, John
NEURO-ONCOLOGY, 2019, 21 : 18 - 18
[4] Health-related quality of life (HRQL) in VERTU: A randomized phase II trial of veliparib (V), radiotherapy (RT), and temozolomide (TMZ) for newly diagnosed MGMT unmethylated (uMGMT) glioblastoma (GBM).
Sim, Hao-Wen
Barnes, Elizabeth
Lwin, Zarnie
Rosenthal, Mark
Wheeler, Helen
Koh, Eng-Siew
Foote, Matthew C.
Fisher, Lauren
Leonard, Robyn
Hall, Merryn
Simes, John
Khasraw, Mustafa
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[5] NUTMEG: A RANDOMISED PHASE II STUDY OF NIVOLUMAB AND TEMOZOLOMIDE (TMZ) VS TMZ ALONE IN ELDERLY PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (GBM): TRIAL IN PROGRESS
Khasraw, Mustafa
McDonald, Kerrie
Yip, Sonia
Verhaak, Roel
Heimberger, Amy
Hall, Merryn
Fisher, Lauren
Barnes, Elizabeth
Rosenthal, Mark
Gedye, Craig
Hovey, Elizabeth
Ellingson, Benjamin
Simes, John
Tognela, Annette
Koh, Eng-Siew
Gan, Hui
Back, Michael
Lwin, Zarnie
NEURO-ONCOLOGY, 2018, 20 : 235 - 235
[6] PHASE III TRIAL OF CCNU/TEMOZOLOMIDE (TMZ) COMBINATION THERAPY VS. STANDARD TMZ THERAPY FOR NEWLY DIAGNOSED MGMT-METHYLATED GLIOBLASTOMA PATIENTS: THE CeTeg/NOA-09 trial
Herrlinger, Ulrich
Tzaridis, Theophilos
Mack, Frederic
Steinbach, Joachim
Schlegel, Uwe
Sabel, Michael
Hau, Peter
Kortman, Rolf-Dieter
Krex, Dietmar
Grauer, Oliver
Goldbrunner, Roland
Schnell, Oliver
Baehr, Oliver
Uhl, Martin
Tabatabai, Ghazaleh
Ringel, Florian
Schmidt-Graf, Friederike
Brehmer, Stefanie
Weyerbrock, Astrid
Bullinger, Lars
Vajkoczy, Peter
Vatter, Hartmut
Schaefer, Niklas
Kebir, Sied
Weller, Johannes
Stummer, Walter
Simon, Matthias
Keil, Vera
Nelles, Michael
Fimmers, Rolf
Pietsch, Torsten
Hattingen, Elke
Coch, Christoph
Glas, Martin
NEURO-ONCOLOGY, 2017, 19 : 13 - 14
[7] QUALITY OF LIFE IN THE PHASE III CeTeG/NOA-09 TRIAL RANDOMIZING CCNU/TEMOZOLOMIDE (TMZ) COMBINATION THERAPY VS. STANDARD TMZ THERAPY FOR NEWLY DIAGNOSED MGMT-METHYLATED GLIOBLASTOMA
Weller, Johannes
Tzaridis, Theophilos
Steinbach, Joachim
Schlegel, Uwe
Hau, Peter
Krex, Dietmar
Grauer, Oliver
Goldbrunner, Roland
Baehr, Oliver
Uhl, Martin
Seidel, Clemens
Tabatabai, Ghazaleh
Bullinger, Lars
Galldiks, Norbert
Schaub, Christina
Stummer, Walter
Simon, Matthias
Fimmers, Rolf
Matthias, Schmid
Coch, Christoph
Glas, Martin
Herrlinger, Ulrich
Schaefer, Niklas
NEURO-ONCOLOGY, 2018, 20 : 218 - 219
[8] CeCil: A randomized, noncomparative phase II clinical trial of the effect of radiation therapy (RT) plus temozolomide (TMZ) combined with cilengitide or cetuximab on the 1-year overall survival of patients with newly diagnosed MGMT-promoter unmethylated glioblastoma.
Verschaeve, V.
D'Hondt, L. A.
Verbeke, L. M. J.
Van Fraeyenhove, F.
Du Four, S.
Duerinck, J.
Neyns, B.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
[9] NRG ONCOLOGY NRG-BN006: A PHASE II/III RANDOMIZED, OPEN-LABEL STUDY OF TOCA 511 AND TOCA FC WITH STANDARD OF CARE COMPARED TO STANDARD OF CARE IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA
Ahluwalia, Manmeet
Pugh, Stephanie
Ellingson, Benjamin
Kotecha, Rupesh
Cloughesy, Timothy
Vogelbaum, Michael
Aldapec, Kenneth
Cu, Yunfeng
Armstrong, Terri
Mehta, Minesh
NEURO-ONCOLOGY, 2019, 21 : 220 - 221
[10] A randomized, phase 3, open-label study of nivolumab versus temozolomide (TMZ) in combination with radiotherapy (RT) in adult patients (pts) with newly diagnosed, O-6-methylguanine DNA methyltransferase (MGMT)-unmethylated glioblastoma (GBM): CheckMate-498.
Sampson, John H.
Omuro, Antonio Marcilio Padula
Preusser, Matthias
Lim, Michael
Butowski, Nicholas A.
Cloughesy, Timothy Francis
Strauss, Lewis C.
Latek, Robert Raymond
Paliwal, Prashni
Weller, Michael
Reardon, David A.
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)

← 1 2 →